The primary objective of this phase II trial is to determine tumor overall response rate
(ORR) in molecularly selected patients with measurable disease as assessed by the Response
Evaluation Criteria in Solid Tumors (RECIST), before versus after 16 weeks of treatment
across tumor types in each arm of the study.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph Paul Eder
Collaborators:
Dana-Farber Cancer Institute The Cleveland Clinic Vanderbilt-Ingram Cancer Center